期刊论文详细信息
Journal of Hematology & Oncology
Exosomes in cancer: small particle, big player
Wenrong Xu1  Hui Qian1  Lijun Wu1  Hui Shi1  Xiao Yuan1  Xu Zhang1 
[1] Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, Jiangsu, China
关键词: Target;    Biomarker;    Cancer;    Intercellular communication;    Exosomes;   
Others  :  1219901
DOI  :  10.1186/s13045-015-0181-x
 received in 2015-03-28, accepted in 2015-06-30,  发布年份 2015
PDF
【 摘 要 】

Exosomes have emerged as a novel mode of intercellular communication. Exosomes can shuttle bioactive molecules including proteins, DNA, mRNA, as well as non-coding RNAs from one cell to another, leading to the exchange of genetic information and reprogramming of the recipient cells. Increasing evidence suggests that tumor cells release excessive amount of exosomes, which may influence tumor initiation, growth, progression, metastasis, and drug resistance. In addition, exosomes transfer message from tumor cells to immune cells and stromal cells, contributing to the escape from immune surveillance and the formation of tumor niche. In this review, we highlight the recent advances in the biology of exosomes as cancer communicasomes. We review the multifaceted roles of exosomes, the small secreted particles, in communicating with other cells within tumor microenvironment. Given that exosomes are cell type specific, stable, and accessible from body fluids, exosomes may provide promising biomarkers for cancer diagnosis and represent new targets for cancer therapy.

【 授权许可】

   
2015 Zhang et al.

【 预 览 】
附件列表
Files Size Format View
20150719092715447.pdf 1087KB PDF download
Fig. 2. 76KB Image download
Fig. 1. 92KB Image download
【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】
  • [1]Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-579.
  • [2]Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F et al.. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319(5867):1244-1247.
  • [3]Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A et al.. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012; 14(7):677-685.
  • [4]Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A et al.. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010; 12(1):1-13.
  • [5]Hsu C, Morohashi Y, Yoshimura S, Manrique-Hoyos N, Jung S, Lauterbach MA et al.. Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. J Cell Biol. 2010; 189(2):223-232.
  • [6]Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003; 278(22):20083-20090.
  • [7]Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A et al.. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009; 284(49):34211-34222.
  • [8]Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI et al.. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005; 105(4):1734-1741.
  • [9]Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006; 66(9):4795-4801.
  • [10]Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC et al.. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008; 15(11):1723-1733.
  • [11]Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013; 288(14):10093-10099.
  • [12]Riches A, Campbell E, Borger E, Powis S. Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway. Eur J Cancer. 2014; 50(5):1025-1034.
  • [13]Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature. 2007; 450(7168):435-439.
  • [14]Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F et al.. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005; 106(1):216-223.
  • [15]Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J Cell Biochem. 2010; 111(2):488-496.
  • [16]Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF et al.. Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010; 11(5):675-687.
  • [17]Escrevente C, Keller S, Altevogt P, Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011; 11:108.
  • [18]Christianson HC, Svensson KJ, van Kuppevelt TH, Li JP, Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci U S A. 2013; 110(43):17380-17385.
  • [19]Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B et al.. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014; 24(6):766-769.
  • [20]Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-659.
  • [21]Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C et al.. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014; 3:26913.
  • [22]Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K et al.. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014; 32(4):983-997.
  • [23]Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A et al.. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26(5):707-721.
  • [24]Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B et al.. Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood. 2014; 123(14):2189-2198.
  • [25]Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S et al.. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer. 2009; 100(7):1073-1086.
  • [26]Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al.. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10(5):619-624.
  • [27]Soldevilla B, Rodriguez M, San Millan C, Garcia V, Fernandez-Perianez R, Gil-Calderon B et al.. Tumor-derived exosomes are enriched in DeltaNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival. Hum Mol Genet. 2014; 23(2):467-478.
  • [28]Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014; 348(1–2):71-76.
  • [29]Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M et al.. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123(4):1542-1555.
  • [30]Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W et al.. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010; 9(6):1085-1099.
  • [31]Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M et al.. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010; 70(4):1668-1678.
  • [32]Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M et al.. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013; 110(18):7312-7317.
  • [33]Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR et al.. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-515.
  • [34]Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013; 32(22):2747-2755.
  • [35]Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013; 288(48):34343-34351.
  • [36]Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124(25):3748-3757.
  • [37]Aga M, Bentz GL, Raffa S, Torrisi MR, Kondo S, Wakisaka N et al.. Exosomal HIF1alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 2014; 33(37):4613-4622.
  • [38]Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B et al.. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 2014; 74(20):5758-5771.
  • [39]Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al.. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-891.
  • [40]Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin AK. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci U S A. 2014; 111(2):711-716.
  • [41]Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2013; 65(3):383-390.
  • [42]Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E et al.. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151(7):1542-1556.
  • [43]Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q et al.. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol. 2012; 188(12):5954-61.
  • [44]Yang M, Chen J, Su F, Yu B, Lin L, Liu Y et al.. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011; 10:117.
  • [45]Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X et al.. Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer. 2014; 110(5):1199-1210.
  • [46]Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R et al.. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012; 109(31):E2110-2116.
  • [47]Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK et al.. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015; 17(6):816-826.
  • [48]Zomer A, Maynard C, Verweij FJ, Kamermans A, Schafer R, Beerling E et al.. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015; 161(5):1046-1057.
  • [49]Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R et al.. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012; 7(12):e50999.
  • [50]Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y et al.. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014; 147(2):423-431.
  • [51]Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003; 63(15):4331-4337.
  • [52]Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W et al.. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005; 4(10):1595-1604.
  • [53]Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F et al.. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A. 2006; 103(26):9903-9907.
  • [54]Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M et al.. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011; 108(37):15336-15341.
  • [55]Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M et al.. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012; 227(2):658-667.
  • [56]Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S et al.. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother. 2011; 60(5):639-648.
  • [57]Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L et al.. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007; 178(11):6867-6875.
  • [58]Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007; 67(15):7458-7466.
  • [59]Mrizak D, Martin N, Barjon C, Jimenez-Pailhes AS, Mustapha R, Niki T et al.. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst. 2014; 107(1):363.
  • [60]Ye SB, Li ZL, Luo DH, Huang BJ, Chen YS, Zhang XS et al.. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014; 5(14):5439-5452.
  • [61]Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J et al.. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009; 124(11):2621-2633.
  • [62]Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z et al.. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010; 176(5):2490-2499.
  • [63]Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP et al.. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120(2):457-471.
  • [64]Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D et al.. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci Rep. 2014; 4:5750.
  • [65]Lundholm M, Schroder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L et al.. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 2014; 9(9):e108925.
  • [66]Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010; 70(23):9621-9630.
  • [67]Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R et al.. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2015; 34(3):290-302.
  • [68]Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L et al.. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-beta/Smad pathway. PLoS One. 2012; 7(12):e52465.
  • [69]Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol. 2012; 40(1):130-138.
  • [70]Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T et al.. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014; 159(3):499-513.
  • [71]Garnier D, Magnus N, Lee TH, Bentley V, Meehan B, Milsom C et al.. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem. 2012; 287(52):43565-43572.
  • [72]Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110(1):13-21.
  • [73]Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7(3):e30679.
  • [74]Wang W, Chen Y. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014; 7(1):86.
  • [75]Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al.. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-1476.
  • [76]Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009; 10(1):42-46.
  • [77]Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D et al.. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013; 288(37):26888-26897.
  • [78]Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO et al.. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009; 100(10):1603-1607.
  • [79]Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem. 2011; 57(1):18-32.
  • [80]Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M et al.. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013; 119(6):1159-1167.
  • [81]Kogure T, Yan IK, Lin WL, Patel T. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer. 2013; 4(7–8):261-272.
  • [82]Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014; 4:458-467.
  • [83]Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L et al.. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2015; 36(3):2007-2012.
  • [84]Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M et al.. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. 2014; 31(9):148.
  • [85]Pitt JM, Charrier M, Viaud S, Andre F, Besse B, Chaput N et al.. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol. 2014; 193(3):1006-1011.
  • [86]Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al.. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4(5):594-600.
  • [87]Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C et al.. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303.
  • [88]Tan A, De La Pena H, Seifalian AM. The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine. 2010; 5:889-900.
  • [89]Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012; 10:134.
  • [90]van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G. Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev. 2013; 65(3):331-335.
  • [91]Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013; 11:88.
  • [92]Zhang Y, Li L, Yu J, Zhu D, Li X, Gu H et al.. Microvesicle-mediated delivery of transforming growth factor beta1 siRNA for the suppression of tumor growth in mice. Biomaterials. 2014; 35(14):4390-4400.
  • [93]Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-345.
  • [94]Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ et al.. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014; 35(7):2383-2390.
  • [95]Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015; 199:145-155.
  • [96]Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E et al.. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014; 192:262-270.
  • [97]Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE et al.. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics. 2013; 12(2):343-355.
  • [98]Fedele C, Singh A, Zerlanko BJ, Iozzo RV, Languino LR. The alphavbeta6 integrin is transferred intercellularly via exosomes. J Biol Chem. 2015; 290(8):4545-4551.
  • [99]Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis. 2011; 16(1):1-12.
  • [100]Menck K, Klemm F, Gross JC, Pukrop T, Wenzel D, Binder C. Induction and transport of Wnt5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles. Oncotarget. 2013; 4(11):2057-2066.
  • [101]Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011; 187(2):676-683.
  • [102]Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 2015; 6(2):715-731.
  • [103]Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008; 180(11):7249-7258.
  • [104]Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M et al.. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010; 70(2):481-489.
  • [105]Xiao H, Lasser C, Shelke GV, Wang J, Radinger M, Lunavat TR et al.. Mast cell exosomes promote lung adenocarcinoma cell proliferation—role of KIT-stem cell factor signaling. Cell Commun Signal. 2014; 12:64.
  • [106]Diao J, Yang X, Song X, Chen S, He Y, Wang Q et al.. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol. 2015; 32(2):453.
  • [107]Sagar G, Sah RP, Javeed N, Dutta SK, Smyrk TC, Lau JS, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut 2015, doi:gutjnl-2014-308350
  • [108]Deng Z, Mu J, Tseng M, Wattenberg B, Zhuang X, Egilmez NK et al.. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nat Commun. 2012; 6:6956.
  • [109]Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y et al.. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012; 31(17):3513-3523.
  • [110]Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014; 13:256.
  • [111]Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL et al.. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One. 2014; 9(4):e95240.
  • [112]Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011; 54(4):1237-1248.
  • [113]Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J et al.. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015; 17(2):183-194.
  • [114]Bovy N, Blomme B, Freres P, Dederen S, Nivelles O, Lion M et al.. Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. 2015; 6(12):10253-10266.
  • [115]Gernapudi R, Yao Y, Zhang Y, Wolfson B, Roy S, Duru N et al.. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer. Breast Cancer Res Treat. 2015; 150(3):685-695.
  • [116]Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA et al.. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011; 71(5):1550-1560.
  • [117]Hong CS, Muller L, Boyiadzis M, Whiteside TL. Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One. 2014; 9(8):e103310.
  • [118]Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK et al.. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. 2014; 192(2):583-592.
  • [119]Eichelser C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H, Pantel K et al.. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014; 5(20):9650-9663.
  • [120]Liu J, Sun H, Wang X, Yu Q, Li S, Yu X et al.. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci. 2014; 15(1):758-773.
  • [121]Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K et al.. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014; 9(4):e92921.
  • [122]Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H et al.. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014; 5:3591.
  • [123]Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer 2015, doi:bjc2015201
  • [124]Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H et al.. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015; 112(3):532-538.
  • [125]Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014; 2014:864894.
  • [126]Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis. 2011; 32(15):1976-1983.
  • [127]Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M et al.. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009; 4(4):e5219.
  • [128]Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E et al.. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009; 113(9):1957-1966.
  • [129]Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009; 9:244.
  • [130]Madhavan B, Yue S, Galli U, Rana S, Gross W, Muller M et al.. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015; 136(11):2616-27.
  • [131]Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F et al.. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One. 2013; 8(7):e70047.
  • [132]Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A et al.. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737.
  • [133]Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z et al.. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009; 7:4.
  • [134]Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R et al.. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015; 67(1):33-41.
  • [135]Isin M, Uysaler E, Ozgur E, Koseoglu H, Sanli O, Yucel OB et al.. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Front Genet. 2015; 6:168.
  文献评价指标  
  下载次数:10次 浏览次数:6次